Lista de obras - Martin Hutchings - Dominio Público Uruguay

(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.

artículo científico publicado en 2014

123 I-MIBG imaging for detection of anthracycline-induced cardiomyopathy

artículo científico publicado en 2017

123I-MIBG for detection of subacute doxorubicin-induced cardiotoxicity in patients with malignant lymphoma

artículo científico publicado en 2018

A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait.

artículo científico publicado en 2015

A small change makes a big difference in Hodgkin lymphoma

scientific article published on 01 November 2018

Advances in the diagnosis and treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma

Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

scientific article published on 01 March 2020

Cancer mortality does not differ between migrants and Danish-born patients

artículo científico publicado en 2014

Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.

artículo científico publicado en 2007

Clinical presentation and staging of Hodgkin lymphoma

artículo científico publicado en 2016

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

scientific article published on 09 April 2020

Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose / Positron Emission Tomography in advanced Hodgkin lymphoma

artículo científico publicado en 2017

Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients

artículo científico publicado en 2020

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

scientific article published on 21 December 2020

Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake.

artículo científico publicado en 2006

ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients

artículo científico publicado en 2018

ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia

artículo científico publicado en 2018

Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial

artículo científico publicado en 2017

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

artículo científico publicado en 2007

Early interim PET scan in Hodgkin lymphoma: where do we stand?

artículo científico publicado en 2008

Evaluation of Response After Radiotherapy for Hodgkin Lymphoma

artículo científico publicado en 2010

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

artículo científico publicado en 2005

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

artículo científico publicado en 2005

FDG-PET in the clinical management of Hodgkin lymphoma.

artículo científico publicado en 2004

FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?

artículo científico publicado en 2014

FDG-PET/CT based response-adapted treatment.

artículo científico publicado en 2012

Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma

artículo científico

Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review

artículo científico publicado en 2009

Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

scientific article published on 01 October 2018

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

artículo científico publicado en 2014

How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?

artículo científico publicado el 1 de enero de 2012

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

artículo científico publicado en 2018

Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography

artículo científico publicado en 2015

Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies.

artículo científico

Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk

artículo científico publicado en 2020

Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement

artículo científico publicado en 2014

Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography

scientific article published on 01 September 2018

In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma

artículo científico publicado en 2014

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

artículo científico publicado en 2017

International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.

artículo científico publicado en 2013

Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group

artículo científico publicado en 2017

Little value of surveillance magnetic resonance imaging for primary CNS lymphomas in first remission: results from a Danish Multicentre Study.

artículo científico publicado en 2016

Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials

artículo científico publicado en 2020

New clues to the prognostic challenge of Hodgkin lymphoma

scientific article published on 19 November 2014

No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.

artículo científico publicado en 2016

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

artículo científico publicado en 2014

Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.

artículo científico publicado en 2015

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

PET imaging in lymphoma ⬇️

artículo científico publicado el 1 de junio de 2009

PET-adapted treatment of Hodgkin lymphoma

scientific article published on 01 October 2019

PET/CT for Staging; Past, Present, and Future.

artículo científico publicado en 2017

PET/CT for therapy response assessment in lymphoma

scientific article published on 20 April 2009

PET/CT in the management of haematological malignancies

artículo científico publicado en 2008

Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study

artículo científico publicado en 2018

Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.

artículo científico publicado en 2006

Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs.

artículo científico publicado en 2011

Pre-transplant positron emission tomography/computed tomography (PET/CT) in relapsed Hodgkin lymphoma: time to shift gears for PET-positive patients? ⬇️

artículo científico publicado el 18 de julio de 2011

Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients.

artículo científico publicado en 2017

Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma.

artículo científico publicado en 2013

Prognostic value of baseline metabolic tumor volume in early stage Hodgkin's lymphoma in the standard arm of H10 trial

artículo científico publicado en 2018

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

artículo científico publicado en 2005

Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al

artículo científico publicado en 2015

Reply to G. Keramida et al.

artículo científico publicado en 2015

Reply to H.J adams et al: "Is FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?".

artículo científico publicado en 2015

Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.

artículo científico publicado en 2017

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

artículo científico publicado en 2014

Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma.

artículo científico

Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study

artículo científico publicado en 2015

Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma

artículo científico publicado en 2012

Routine follow-up scanning of patients with lymphoma: who, when, how, and why?

artículo científico publicado en 2011

Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients

article

Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up.

artículo científico publicado en 2016

Suspected Richter transformation: positron emission tomography/computed tomography tells us who should have a biopsy and where

artículo científico publicado en 2013

Targeted immunotherapy in Hodgkin lymphoma

artículo científico publicado en 2015

The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.

artículo científico publicado en 2017

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

artículo científico publicado en 2014

The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma.

artículo científico publicado en 2005

The role of bone marrow biopsy in Hodgkin lymphoma staging: “To be, or not to be, that is the question”? ⬇️

artículo científico publicado el 1 de abril de 2012

The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study

artículo científico publicado en 2016

Treatment of Hodgkin lymphoma: the past, present, and future.

artículo científico publicado en 2008

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.

artículo científico publicado en 2018

Uptake of FDG in Lemierre's syndrome with normal leucocyte scintigraphy.

artículo científico publicado en 2003

Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.

artículo científico publicado en 2016

Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.

artículo científico

When and how to perform surveillance imaging in patients with lymphoma, and is it worth it?

artículo científico publicado en 2012

Lista de obras de Martin Hutchings

(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.

123 I-MIBG imaging for detection of anthracycline-induced cardiomyopathy

123I-MIBG for detection of subacute doxorubicin-induced cardiotoxicity in patients with malignant lymphoma

A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait.

A small change makes a big difference in Hodgkin lymphoma

Advances in the diagnosis and treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma

Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Cancer mortality does not differ between migrants and Danish-born patients

Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.

Clinical presentation and staging of Hodgkin lymphoma

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose / Positron Emission Tomography in advanced Hodgkin lymphoma

Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake.

ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients

ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia

Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

Early interim PET scan in Hodgkin lymphoma: where do we stand?

Evaluation of Response After Radiotherapy for Hodgkin Lymphoma

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

FDG-PET in the clinical management of Hodgkin lymphoma.

FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?

FDG-PET/CT based response-adapted treatment.

Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma

Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review

Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography

Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies.

Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk

Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement

Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography

In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.

Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group

Little value of surveillance magnetic resonance imaging for primary CNS lymphomas in first remission: results from a Danish Multicentre Study.

Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials

New clues to the prognostic challenge of Hodgkin lymphoma

No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

PET imaging in lymphoma ⬇️

PET-adapted treatment of Hodgkin lymphoma

PET/CT for Staging; Past, Present, and Future.

PET/CT for therapy response assessment in lymphoma

PET/CT in the management of haematological malignancies

Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study

Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.

Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs.

Pre-transplant positron emission tomography/computed tomography (PET/CT) in relapsed Hodgkin lymphoma: time to shift gears for PET-positive patients? ⬇️

Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients.

Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma.

Prognostic value of baseline metabolic tumor volume in early stage Hodgkin's lymphoma in the standard arm of H10 trial

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al

Reply to G. Keramida et al.

Reply to H.J adams et al: "Is FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?".

Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma.

Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study

Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma

Routine follow-up scanning of patients with lymphoma: who, when, how, and why?

Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients

Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up.

Suspected Richter transformation: positron emission tomography/computed tomography tells us who should have a biopsy and where

Targeted immunotherapy in Hodgkin lymphoma

The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma.